FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005062125> ?p ?o ?g. }

• W2005062125 endingPage "26.e1" @default.
• W2005062125 startingPage "14" @default.
• W2005062125 abstract "IntroductionThe purpose of this study was to assess the efficacy and safety of FOLFOX4, comprising infusional 5-fluorouracil (5-FU)/leucovorin (LV) and oxaliplatin, with cetuximab compared with UFOX, comprising UFT, an oral prodrug of 5-FU, LV, and oxaliplatin, with cetuximab as first-line treatment for mCRC.Patients and MethodsPatients, unselected by tumor KRAS status, were randomized 1:1 to FOLFOX4 with cetuximab or UFOX with cetuximab. Treatment was continued until disease progression or unacceptable toxicity. The primary end point, assessed in the intention-to-treat population, was progression-free survival (PFS). Secondary end points included tumor response, overall survival, and safety. Outcome according to KRAS mutation status was investigated.ResultsRecruitment was curtailed at 302 patients after reporting of the importance of tumor KRAS mutation status for cetuximab activity. Baseline characteristics were balanced between treatment groups. PFS was significantly longer in the FOLFOX4 with cetuximab group compared with UFOX with cetuximab group (median 8.2 vs. 6.6 months; hazard ratio, 0.68; 95% confidence interval [CI], 0.52-0.89; P = .0048). The response rate was also significantly greater in the FOLFOX4 with cetuximab group (51.3% vs. 37.5%, respectively; odds ratio, 1.76; 95% CI, 1.11-2.78; P = .0160), although overall survival was comparable. In the KRAS wild type subgroup, efficacy outcomes were similar to those in the intention-to-treat population. Side effect profiles were manageable and consistent with expectations.ConclusionIn the first-line treatment of mCRC, UFOX with cetuximab had an acceptable safety profile but inferior activity compared with FOLFOX4 with cetuximab in relation to PFS and response. The regimens were comparable with regard to overall survival." @default.
• W2005062125 created "2016-06-24" @default.
• W2005062125 creator A5008564423 @default.
• W2005062125 creator A5012446712 @default.
• W2005062125 creator A5012852394 @default.
• W2005062125 creator A5020075524 @default.
• W2005062125 creator A5027646786 @default.
• W2005062125 creator A5049146702 @default.
• W2005062125 creator A5071569707 @default.
• W2005062125 creator A5084768366 @default.
• W2005062125 date "2014-03-01" @default.
• W2005062125 modified "2023-10-03" @default.
• W2005062125 title "FOLFOX4 With Cetuximab vs. UFOX With Cetuximab as First-Line Therapy in Metastatic Colorectal Cancer: The Randomized Phase II FUTURE Study" @default.
• W2005062125 cites W121414984 @default.
• W2005062125 cites W1874410314 @default.
• W2005062125 cites W1982336200 @default.
• W2005062125 cites W1994869603 @default.
• W2005062125 cites W1995961103 @default.
• W2005062125 cites W2011391447 @default.
• W2005062125 cites W2032541464 @default.
• W2005062125 cites W2063415077 @default.
• W2005062125 cites W2069419271 @default.
• W2005062125 cites W2078498260 @default.
• W2005062125 cites W2078602902 @default.
• W2005062125 cites W2087163755 @default.
• W2005062125 cites W2095201384 @default.
• W2005062125 cites W2098354753 @default.
• W2005062125 cites W2103359811 @default.
• W2005062125 cites W2112727687 @default.
• W2005062125 cites W2118971132 @default.
• W2005062125 cites W2121368761 @default.
• W2005062125 cites W2123135306 @default.
• W2005062125 cites W2128447158 @default.
• W2005062125 cites W2133399075 @default.
• W2005062125 cites W2134142320 @default.
• W2005062125 cites W2139119404 @default.
• W2005062125 cites W2139168548 @default.
• W2005062125 cites W2139248078 @default.
• W2005062125 cites W2142564546 @default.
• W2005062125 cites W2144425748 @default.
• W2005062125 cites W2145070131 @default.
• W2005062125 cites W2166127437 @default.
• W2005062125 cites W2168377135 @default.
• W2005062125 cites W2330116523 @default.
• W2005062125 cites W2409420104 @default.
• W2005062125 cites W2589823065 @default.
• W2005062125 cites W4385789423 @default.
• W2005062125 doi "https://doi.org/10.1016/j.clcc.2013.11.009" @default.
• W2005062125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24370353" @default.
• W2005062125 hasPublicationYear "2014" @default.
• W2005062125 type Work @default.
• W2005062125 sameAs 2005062125 @default.
• W2005062125 citedByCount "18" @default.
• W2005062125 countsByYear W20050621252014 @default.
• W2005062125 countsByYear W20050621252015 @default.
• W2005062125 countsByYear W20050621252017 @default.
• W2005062125 countsByYear W20050621252018 @default.
• W2005062125 countsByYear W20050621252019 @default.
• W2005062125 countsByYear W20050621252020 @default.
• W2005062125 countsByYear W20050621252021 @default.
• W2005062125 countsByYear W20050621252022 @default.
• W2005062125 countsByYear W20050621252023 @default.
• W2005062125 crossrefType "journal-article" @default.
• W2005062125 hasAuthorship W2005062125A5008564423 @default.
• W2005062125 hasAuthorship W2005062125A5012446712 @default.
• W2005062125 hasAuthorship W2005062125A5012852394 @default.
• W2005062125 hasAuthorship W2005062125A5020075524 @default.
• W2005062125 hasAuthorship W2005062125A5027646786 @default.
• W2005062125 hasAuthorship W2005062125A5049146702 @default.
• W2005062125 hasAuthorship W2005062125A5071569707 @default.
• W2005062125 hasAuthorship W2005062125A5084768366 @default.
• W2005062125 hasBestOaLocation W20050621251 @default.
• W2005062125 hasConcept C121608353 @default.
• W2005062125 hasConcept C126322002 @default.
• W2005062125 hasConcept C143998085 @default.
• W2005062125 hasConcept C156957248 @default.
• W2005062125 hasConcept C168563851 @default.
• W2005062125 hasConcept C203092338 @default.
• W2005062125 hasConcept C207103383 @default.
• W2005062125 hasConcept C2776694085 @default.
• W2005062125 hasConcept C2779998722 @default.
• W2005062125 hasConcept C2780739268 @default.
• W2005062125 hasConcept C2780962732 @default.
• W2005062125 hasConcept C2781187634 @default.
• W2005062125 hasConcept C2908647359 @default.
• W2005062125 hasConcept C44249647 @default.
• W2005062125 hasConcept C526805850 @default.
• W2005062125 hasConcept C71924100 @default.
• W2005062125 hasConcept C99454951 @default.
• W2005062125 hasConceptScore W2005062125C121608353 @default.
• W2005062125 hasConceptScore W2005062125C126322002 @default.
• W2005062125 hasConceptScore W2005062125C143998085 @default.
• W2005062125 hasConceptScore W2005062125C156957248 @default.
• W2005062125 hasConceptScore W2005062125C168563851 @default.
• W2005062125 hasConceptScore W2005062125C203092338 @default.
• W2005062125 hasConceptScore W2005062125C207103383 @default.
• W2005062125 hasConceptScore W2005062125C2776694085 @default.
• W2005062125 hasConceptScore W2005062125C2779998722 @default.

• next